{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:02:07Z","timestamp":1773270127826,"version":"3.50.1"},"reference-count":29,"publisher":"Oncology Nursing Society (ONS)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2015,12,1]]},"DOI":"10.1188\/15.cjon.e131-e139","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T10:20:24Z","timestamp":1447928424000},"page":"E131-E139","source":"Crossref","is-referenced-by-count":10,"title":["Optimizing Care and Compliance for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel"],"prefix":"10.1188","volume":"19","author":[{"given":"Allister","family":"Benjamin Chase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Markel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Tawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2015,12,1]]},"reference":[{"key":"1","unstructured":"Actelion Pharmaceuticals Inc. (2013). Valchlor\u00ae (prescribing information) [Package insert]. San Francisco, CA: Author."},{"key":"2","doi-asserted-by":"crossref","unstructured":"Agar, N.S., Wedgeworth, E., Crichton, S., Mitchell, T.J., Cox, M., Ferreira, S., . . . Whittaker, S.J. (2010). Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: Validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal. Journal of Clinical Oncology, 28, 4730\u20134739.","DOI":"10.1200\/JCO.2009.27.7665"},{"key":"3","unstructured":"American Academy of Dermatology. (2015). Atopic dermatitis. Retrieved from http:\/\/www.aad.org\/dermatology-a-to-z\/diseases -and-treatments\/a---d\/atopic-dermatitis"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Bradford, P.T., Devesa, S.S., Anderson, W.F., & Toro, J.R. (2009). Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3884 cases. Blood, 113, 5064\u20135073.","DOI":"10.1182\/blood-2008-10-184168"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Criscione, V.D., & Weinstock, M.A. (2007). Incidence of cutaneous T-cell lymphoma in the United States, 1973\u20132002. Archives of Dermatology, 143, 854\u2013859.","DOI":"10.1001\/archderm.143.7.854"},{"key":"6","unstructured":"Cutaneous Lymphoma Foundation. (2011). Cutaneous T-cell lymphoma. Retrieved from http:\/\/www.clfoundation.org\/sites\/default\/files\/content\/CTCL_2011.pdf"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Demierre, M.F., Gan, S., Jones, J., & Miller, D.R. (2006). Significant impact of cutaneous T-cell lymphoma on patients\u2019 quality of life. Cancer, 107, 2504\u20132511.","DOI":"10.1002\/cncr.22252"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Girardi, M., Heald, P.W., & Wilson, L.D. (2004). The pathogenesis of mycosis fungoides. New England Journal of Medicine. 350, 1978\u20131988.","DOI":"10.1056\/NEJMra032810"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Goodman, L.S., Wintrobe, M.M., Dameshek, W., Goodman, M.J., Gilman, A., & McLennan, M.T. (1946). Nitrogen mustard therapy: Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin\u2019s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA, 132, 126\u2013132.","DOI":"10.1001\/jama.1946.02870380008004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Imam, M.H., Shenoy, P.J., Flowers, C.R., Phillips, A., & Lechowicz, M.J. (2013). Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leukemia and Lymphoma, 54, 752\u2013759.","DOI":"10.3109\/10428194.2012.729831"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Jawed, S.I., Myskowski, P.L., Horwitz, S., Moskowitz, A., & Querfeld, C. (2014). Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): Part II. Prognosis, management, and future directions. Journal of the American Academy of Dermatology, 70(2), e1\u2013e17.","DOI":"10.1016\/j.jaad.2013.07.049"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Kim, E.J., Hess, S., Richardson, S.K., Newton, S., Showe, L.C., Benoit, B.M., . . . Rook, A.H. (2005). Immunopathogenesis and therapy of cutaneous T-cell lymphoma. Journal of Clinical Investigation, 115, 798\u2013812.","DOI":"10.1172\/JCI200524826"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Kim, Y.H., Duvic, M., Guitart, J., & Lessin, S.R. (January 23\u201325, 2014). Tolerability and efficacy of mechlorethamine 0.04% gel in CTCL (mycosis fungoides) after initial treatment with topical mechlorethamine 0.02% gel [Poster TS14_10]. Presented at the T-cell Lymphoma Forum in San Francisco, CA.","DOI":"10.1200\/jco.2014.32.15_suppl.9093"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Kim, Y.H., Martinez, G., Varghese, A., & Hoppe, R.T. (2003). Topical nitrogen mustard in the management of mycosis fungoides: Update of the Stanford experience. Archives of Dermatology, 139, 165\u2013173.","DOI":"10.1001\/archderm.139.2.165"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Korgavkar, K., Xiong, M., & Weinstock, M. (2013). Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatology, 149, 1295\u20131299.","DOI":"10.1001\/jamadermatol.2013.5526"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Lessin, S.R., Duvic, M., Guitart, J., Pandya, A.G., Strober, B.E., Olsen, E.A., . . . Kim, Y.H. (2013). Topical chemotherapy in cutaneous T-cell lymphoma: Positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology, 149, 25\u201332.","DOI":"10.1001\/2013.jamadermatol.541"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Lindahl, L.M., Fenger-Gr\u00f8n, M., & Iversen, L. (2014). Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: A 30-year population-based cohort study. British Journal of Dermatology, 170, 699\u2013704.","DOI":"10.1111\/bjd.12620"},{"key":"18","unstructured":"Lymphoma Research Foundation. (2012). Cutaneous T-cell lymphoma: Types of cutaneous T-cell lymphoma. Retrieved from http:\/\/www.lymphoma.org\/site\/pp.asp?c=bkLTKaOQLmK8E&b=6300151"},{"key":"19","unstructured":"National Comprehensive Cancer Network. (2014). NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin\u2019s lymphomas. Retrieved from: http:\/\/www.nccn.org\/about\/nhl.pdf"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Olsen, E., Vonderheid, E., Pimpinelli, N., Willemze, R., Kim, Y., Knobler, R., . . . Whittaker, S. (2007). Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, 110, 1713\u20131722.","DOI":"10.1182\/blood-2007-03-055749"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Ramsay, D.L., Parnes, R.E., & Dubin, N. (1984). Response of mycosis fungoides to topical chemotherapy with mechlorethamine. Archives of Dermatology, 120, 1585\u20131590.","DOI":"10.1001\/archderm.1984.01650480047016"},{"key":"22","unstructured":"Reavely, M.M., & Wilson, L.D. (2004). Total skin electron beam therapy and cutaneous T-cell lymphoma: A clinical guide for patients and staff. Dermatology Nursing, 16, 36\u201339."},{"key":"23","unstructured":"Salhany, K.E., Cousar, J.B., Greer, J.P., Casey, T.T., Fields, J.P., & Collins, R.D. (1988). Transformation of cutaneous T-cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. American Journal of Pathology, 132, 265\u2013277."},{"key":"24","doi-asserted-by":"crossref","unstructured":"Sarantopoulos, G.P., Palla, B., Said, J., Kinney, M.C., Swerdlow, S.M., Willemze, R., & Binder, S.W. (2013). Mimics of cutaneous lymphoma: Report of the 2011 Society for Hematopathology\/European Association for Haematopathology workshop. American Journal of Clinical Pathology, 139, 536\u2013551.","DOI":"10.1309\/AJCPX4BXTP2QBRKO"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Scarisbrick, J.J., Kim, Y.H., Whittaker, S.J., Wood, G.S., Vermeer, M.H., Prince, H.M., & Quaglino, P. (2014). Prognostic factors, prognostic indices and staging in mycosis fungoides and S\u00e9zary syndrome: Where are we now? British Journal of Dermatology, 170, 1226\u20131236.","DOI":"10.1111\/bjd.12909"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Smedby, K.E., Vajdic, C.M., Falster, M., Engels, E.A., Mart\u00ednez-Maza, O., Turner, J., . . . Cozen, W. (2008). Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. Blood, 111, 4029\u20134038.","DOI":"10.1182\/blood-2007-10-119974"},{"key":"27","unstructured":"Stanford School of Medicine Multidisciplinary Cutaneous Lymphoma Group. (2015). Mycosis fungoides\/S\u00e9zary syndrome. Retrieved from http:\/\/cutaneouslymphoma.stanford.edu\/com munity\/mycosis_fungoides.html"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Trautinger, F., Knobler, R., Willemze, R., Peris, K., Stadler, R., Laroche, L., . . . Whittaker, S. (2006). EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome. European Journal of Cancer, 42, 1014\u20131030.","DOI":"10.1016\/j.ejca.2006.01.025"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Zackheim, H.S., & McCalmont, T.H. (2002). Mycosis fungoides: The great imitator. Journal of the American Academy of Dermatology, 47, 914\u2013918.","DOI":"10.1067\/mjd.2002.124696"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/19\/6\/optimizing-care-and-compliance-treatment-mycosis-fungoides-cutaneous-t-cell-lymphoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:53:01Z","timestamp":1763754781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/19\/6\/optimizing-care-and-compliance-treatment-mycosis-fungoides"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,1]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12,1]]}},"URL":"https:\/\/doi.org\/10.1188\/15.cjon.e131-e139","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,1]]}}}